South Africa takes the lead in HIV prevention with a groundbreaking twice-a-year injection being added to the Essential Medicines List.

Eswatini on Tuesday became the first African country to receive lenacapavir, the first twice-yearly HIV prevention injection hailed by global health officials as a game-changer in the fight against a ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...

Administration officials say South Africa has “significant means” to fund a promising new drug, lenacapavir, on its own.

Over 15 children have been diagnosed with HIV in Karachi’s SITE Town, linked to Valika Hospital, prompting urgent local and ...

Details in the report further indicate that South Buganda has the highest HIV prevalence, followed by Acholi, Ankole, Lango, North Buganda and Kampala ...

More than 74,000 participants in clinical trials lost their access to care as a result of Trump administration cuts, ...

Local political activists put their heads together after first case of infection confirmed in 18-month-old girl.

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...